Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 59

Sort by

Sort Order Select

Journal Articles

Targeting Kinome Reprogramming for Overcoming Ibrutinib-Resistance (IR) in Mantle Cell Lymphoma (MCL)

Xiaohong Zhao, MD PhD, Huijuan Jiang, MD, Michelle Wang, Tao Li, MD, Jing Gao, PhD, Tint Lwin, MD PhD, Yuan Ren, PhD, Eduardo Sotomayor, MD, Bijal D. Shah, MD, Jianguo Tao, MD PhD

Blood (2018) 132 (Supplement 1): 2651.

https://doi.org/10.1182/blood-2018-99-116756

Published: 2018

Journal Articles

C-Myc Driven Tolerogenic Tumor Microenvironment (TME) in Mantle Cell Lymphoma (MCL) Is Overcome By Bromodomain Inhibition

Fengdong Cheng, MD, Yuan Ren, PhD, Jie Chen, PhD, Zi Wang, B.S., Tao Li, MD, Kieron Dunleavy, MD, Jianqing Lin, MD, James Bradner, MD, Mitchell R. Smith, MDPhD, Bijal D. Shah, MD, Eduardo Sotomayor, MD, Jianguo Tao, MD PhD

Blood (2018) 132 (Supplement 1): 777.

https://doi.org/10.1182/blood-2018-99-116865

Published: 2018

Journal Articles

Radiation Therapy As a Bridging Strategy for Refractory Diffuse Large B Cell Lymphoma Patients Awaiting CAR T Manufacturing of Axicabtagene Ciloleucel

Michael D. Jain, MD PhD, Julio C. Chavez, MD, Bijal D. Shah, MD, Farhad Khimani, MBBS, Aleksandr Lazaryan, MD PhD MPH, Marco L. Davila, MD PhD, Hien D. Liu, MD, Aaron D Falchook, MD, Timothy Robinson, MD, Sungjune Kim, MD PhD, Frederick L. Locke, MD

Blood (2018) 132 (Supplement 1): 4220.

https://doi.org/10.1182/blood-2018-99-117133

Published: 2018

Journal Articles

Updated Phase 1 Results of Zuma-3: Kte-C19, an Anti-CD19 Chimeric Antigen Receptor T Cell Therapy, in Adult Patients with Relapsed/Refractory Acute Lymphoblastic Leukemia

Blood (2018) 132 (Supplement 1): 897.

https://doi.org/10.1182/blood-2018-99-111531

Published: 2018

Journal Articles

Long-Term Follow up of Front-Line Therapy with Ofatumumab, High Dose Methylprednisolone and Lenalidomide (HiLO trial) for Treatment-Naïve Chronic Lymphocytic Leukemia

Ariel Felipe Grajales-Cruz, MD, Julio C. Chavez, MD, Elyce P. Turba, MSN, RN, Lisa Nodzon, PhD ARNP, AOCNP, Francisco Perez Leal, MD, Jose Sandoval-Sus, MD, Rami S. Komrokji, MD, Frederick L. Locke, MD, Mohamed A Kharfan-Dabaja, MD, Bijal D. Shah, MD, Lubomir Sokol, MD PhD, Celeste M. Bello, MD, Javier Pinilla Ibarz, MD

Blood (2018) 132 (Supplement 1): 3150.

https://doi.org/10.1182/blood-2018-99-111564

Published: 2018

Journal Articles

A Phase II Study of Brentuximab Vedotin Plus Adriamycin and Dacarbazine without Radiation in Non-Bulky Limited Stage Classical Hodgkin Lymphoma

Jeremy S. Abramson, MD MMSc, Robert A. Redd, MS, Jeffrey A. Barnes, MD PhD, Elizabeth Bengtson, MD, Ronald W. Takvorian, MD, Lubomir Sokol, MD PhD, Frederick Lansigan, MD, Philippe Armand, MD PhD, Bijal D. Shah, MD, Eric D Jacobsen, MD, Donna S Neuberg, ScD, Ann S. LaCasce, MD MSc, Celeste M. Bello, MD

Blood (2018) 132 (Supplement 1): 1654.

https://doi.org/10.1182/blood-2018-99-115173

Published: 2018

Journal Articles

Pharmacoproteomics Identifies PLK1 As Vulnerability for Aggressive B-Cell Lymphomas

Blood (2018) 132 (Supplement 1): 2853.

https://doi.org/10.1182/blood-2018-99-118004

Published: 2018

Journal Articles

Long-Term Follow-up of Acalabrutinib Monotherapy in Patients with Relapsed/Refractory Mantle Cell Lymphoma

Blood (2018) 132 (Supplement 1): 2876.

https://doi.org/10.1182/blood-2018-99-110327

Published: 2018

Journal Articles

Phase 1 Results of ZUMA-3: KTE-C19, an Anti-CD19 Chimeric Antigen Receptor (CAR) T Cell Therapy, in Adult Patients with Relapsed/Refractory Acute Lymphoblastic Leukemia (R/R ALL)

Bijal D. Shah, MD, Wendy Stock, MD, William G Wierda, MD PhD, Olalekan Oluwole, MBBS, MPH, Houston Holmes, MD FACP, Gary J. Schiller, MD FACP, Max S. Topp, MD, Marie José Kersten, MD PhD, Roch Houot, MD PhD, Nicolas Boissel, MD PhD, Michelle Mojadidi, MSc, Allen Xue, PhD, Armen Mardiros, PhD, Yizhou Jiang, PhD, Tong Shen, PhD, Jeff S. Aycock, Shanna Stout, Jeffrey S. Wiezorek, MD MS, Rajul Jain, MD

Blood (2017) 130 (Supplement 1): 888.

https://doi.org/10.1182/blood.V130.Suppl_1.888.888

Published: 2017

Journal Articles

Predictive Simulation Modeling of Early T-Cell Precursor Acute Lymphoblastic Leukemia (ETP-ALL) Patient Genomics Identifies Targeted Combination Treatment Options

Leylah M. Drusbosky, PhD, Ansu Kumar, MS, Shwetha K, BE, Priyanka Bhargav, BE, Ashish Choudhary, MS, Soumyashree L, BE, Shivgonda C. Birajdar, MCA, Kunal Ghosh Roy, MS, Taher Abbasi, MS, MBA, Shireen Vali, PhD, Manju Sengar, MD DM, Girish Chinnaswamy, MD MRCP, Bijal D. Shah, MD, Christopher R. Cogle, MD

Blood (2017) 130 (Supplement 1): 2708.

https://doi.org/10.1182/blood.V130.Suppl_1.2708.2708

Published: 2017

Journal Articles

Venetoclax As a Single Agent and in Combination with PI3K-mTOR1/2 Kinase Inhibitors Against Ibrutinib Sensitive and Resistant Mantle Cell Lymphoma

Huijuan Jiang, MD, Tint Lwin, MD PhD, Bijal D. Shah, MD, Grace T Li, Yuan Ren, Michael W Yan, Lynn C. Moscinski, MD, Xiaohong Zhao, MD PhD, Jianguo Tao, MD PhD

Blood (2017) 130 (Supplement 1): 5197.

https://doi.org/10.1182/blood.V130.Suppl_1.5197.5197

Published: 2017

Journal Articles

Prognostic Impact of Concurrent BCR/ABL1 Gene Rearrangement on Survival Outcome in Ph-like B-ALL Patients

Seongseok Yun, MD PhD, Nicole D. Vincelette, PhD, Jeffrey E. Lancet, MD, Julio C. Chavez, MD, Bijal D. Shah, MD, Ling Zhang, MD

Blood (2017) 130 (Supplement 1): 5114.

https://doi.org/10.1182/blood.V130.Suppl_1.5114.5114

Published: 2017

Journal Articles

Computational Biology Model of ETP-ALL Used to Accurately Classify ETP-ALL Vs Non ETP-ALL Patients with Genomic Input

Leylah M. Drusbosky, PhD, Ansu Kumar, MS, Shwetha K, BE, Sumanth Vasista, BE, Anuj Tyagi, MS, Swaminathan Rajagopalan, MT, Aftab Alam, MS, Taher Abbasi, MS, MBA, Shireen Vali, PhD, Girish Chinnaswamy, MD MRCP, Manju Sengar, MD DM, Bijal D. Shah, MD, Christopher R. Cogle, MD

Blood (2017) 130 (Supplement 1): 1449.

https://doi.org/10.1182/blood.V130.Suppl_1.1449.1449

Published: 2017

Journal Articles

Initial Treatment with Lenalidomide Plus Rituximab for Mantle Cell Lymphoma: 5-Year Follow-up and Correlative Analysis from a Multi-Center Phase II Study

Jia Ruan, MD PhD, Peter Martin, FRCPC, MD MS, Paul J Christos, Dr.P.H., M.S., Leandro Cerchietti, MD, Bijal D. Shah, MD, Stephen J. Schuster, MD, Wayne Tam, MD PhD, Amelyn Rodriguez, BSN, RN, OCN, David Hyman, Maria Nieves Calvo Vidal, PhD, Lidia Roman Gonzalez, Sonali M. Smith, MD, Jakub Svoboda, MD, Richard R. Furman, MD, Morton Coleman, MD, John P. Leonard, MD

Blood (2017) 130 (Supplement 1): 154.

https://doi.org/10.1182/blood.V130.Suppl_1.154.154

Published: 2017

Journal Articles

Role of Somatic Mutations in Clonal Evolution of Chronic Myeloid Leukemia from Chronic Phase to Blast Phase

Chetasi Talati, MD, Leidy Isenalumhe, MD, Andrew Kuykendall, MD, Bijal D. Shah, MD, Julio C. Chavez, MD, Mohammad Omar Hussaini, MD, Javier Pinilla-Ibarz, MD PhD, Kendra L. Sweet, MD

Blood (2017) 130 (Supplement 1): 1587.

https://doi.org/10.1182/blood.V130.Suppl_1.1587.1587

Published: 2017

Journal Articles

Impact of Serum Albumin in the Prognosis of Myc-Positive Aggressive B-Cell Lymphomas: Potential for a Novel Prognostic Score

Chetasi Talati, MD, Andrew Kuykendall, MD, Jori Kaplan, MD, Jose D Sandoval-Sus, MD, Samir Dalia, MD, Bijal D. Shah, MD, Celeste M. Bello, MD, Farhad Khimani, MD, Paul A. Chervenick, MD, Ernesto Ayala, MD, Frederick L. Locke, MD, Mohamed A Kharfan-Dabaja, MD, Eduardo M. Sotomayor, MD, Lubomir Sokol, Julio C. Chavez, MD

Blood (2016) 128 (22): 1870.

https://doi.org/10.1182/blood.V128.22.1870.1870

Published: 2016

Journal Articles

A Phase I Study of Selinexor in Combination with Daunorubicin and Cytarabine in Patients with Newly Diagnosed Poor-Risk Acute Myeloid Leukemia

Kendra L. Sweet, MD, Rami S. Komrokji, MD, Eric Padron, MD, Christopher L Cubitt, PhD, Leyla Khavarian, Alan F List, MD, David Sallman, MD, Daniel Sullivan, Julio C Chavez, MD, Bijal D. Shah, MD, Jeffrey E. Lancet, MD

Blood (2016) 128 (22): 4040.

https://doi.org/10.1182/blood.V128.22.4040.4040

Published: 2016

Journal Articles

Outcomes of Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia after Ibrutinib Discontinuation Outside Clinical Trials: A Single Institution Experience

Jose D Sandoval-Sus, MD, Julio C Chavez, MD, Samir Dalia, MD, Celeste M. Bello, MD, Bijal D. Shah, MD, Viet Q. Ho, PharmD, RPh, BCOP, Lisa Nodzon, PhDANP, Mohamed A. Kharfan-Dabaja, MD, Eduardo M. Sotomayor, MD, Lubomir Sokol, MD PhD, Javier Pinilla-Ibarz

Blood (2015) 126 (23): 2945.

https://doi.org/10.1182/blood.V126.23.2945.2945

Published: 2015

Journal Articles

Myelodysplastic Syndromes in Adolescent Young Adults (AYA)

Joanna (Asia) Grabska, MD, Bijal D. Shah, MD, Najla H. Al Ali, BDS, MSc, Eric Padron, MD, Hanadi Ramadan, BA, Jeffrey E Lancet, MD, Alan F. List, MD, Rami S. Komrokji, MD

Blood (2015) 126 (23): 2898.

https://doi.org/10.1182/blood.V126.23.2898.2898

Published: 2015

Journal Articles

Transition of Intensive Chemotherapy for Acute Lymphoblastic Leukemia (ALL) to the Outpatient Setting: Analysis of Safety and Cost Savings

Timothy E. Kubal, MD MBA, Christopher Rodriguez Salamanca, PA, Julio C Chavez, MD, Bijal D. Shah, MD, Rami S. Komrokji, MD, Viet Q. Ho, PharmD, RPh, BCOP, Jeffrey E Lancet, MD

Blood (2015) 126 (23): 5604.

https://doi.org/10.1182/blood.V126.23.5604.5604

Published: 2015

NARROW

Targeting Kinome Reprogramming for Overcoming Ibrutinib-Resistance (IR) in Mantle Cell Lymphoma (MCL)

C-Myc Driven Tolerogenic Tumor Microenvironment (TME) in Mantle Cell Lymphoma (MCL) Is Overcome By Bromodomain Inhibition

Radiation Therapy As a Bridging Strategy for Refractory Diffuse Large B Cell Lymphoma Patients Awaiting CAR T Manufacturing of Axicabtagene Ciloleucel

Updated Phase 1 Results of Zuma-3: Kte-C19, an Anti-CD19 Chimeric Antigen Receptor T Cell Therapy, in Adult Patients with Relapsed/Refractory Acute Lymphoblastic Leukemia

Long-Term Follow up of Front-Line Therapy with Ofatumumab, High Dose Methylprednisolone and Lenalidomide (HiLO trial) for Treatment-Naïve Chronic Lymphocytic Leukemia

A Phase II Study of Brentuximab Vedotin Plus Adriamycin and Dacarbazine without Radiation in Non-Bulky Limited Stage Classical Hodgkin Lymphoma

Pharmacoproteomics Identifies PLK1 As Vulnerability for Aggressive B-Cell Lymphomas

Long-Term Follow-up of Acalabrutinib Monotherapy in Patients with Relapsed/Refractory Mantle Cell Lymphoma

Phase 1 Results of ZUMA-3: KTE-C19, an Anti-CD19 Chimeric Antigen Receptor (CAR) T Cell Therapy, in Adult Patients with Relapsed/Refractory Acute Lymphoblastic Leukemia (R/R ALL)

Predictive Simulation Modeling of Early T-Cell Precursor Acute Lymphoblastic Leukemia (ETP-ALL) Patient Genomics Identifies Targeted Combination Treatment Options

Venetoclax As a Single Agent and in Combination with PI3K-mTOR1/2 Kinase Inhibitors Against Ibrutinib Sensitive and Resistant Mantle Cell Lymphoma

Prognostic Impact of Concurrent BCR/ABL1 Gene Rearrangement on Survival Outcome in Ph-like B-ALL Patients

Computational Biology Model of ETP-ALL Used to Accurately Classify ETP-ALL Vs Non ETP-ALL Patients with Genomic Input

Initial Treatment with Lenalidomide Plus Rituximab for Mantle Cell Lymphoma: 5-Year Follow-up and Correlative Analysis from a Multi-Center Phase II Study

Role of Somatic Mutations in Clonal Evolution of Chronic Myeloid Leukemia from Chronic Phase to Blast Phase

Impact of Serum Albumin in the Prognosis of Myc-Positive Aggressive B-Cell Lymphomas: Potential for a Novel Prognostic Score

A Phase I Study of Selinexor in Combination with Daunorubicin and Cytarabine in Patients with Newly Diagnosed Poor-Risk Acute Myeloid Leukemia

Outcomes of Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia after Ibrutinib Discontinuation Outside Clinical Trials: A Single Institution Experience

Myelodysplastic Syndromes in Adolescent Young Adults (AYA)

Transition of Intensive Chemotherapy for Acute Lymphoblastic Leukemia (ALL) to the Outpatient Setting: Analysis of Safety and Cost Savings

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only